Avalo Therapeutics (AVTX) announced the appointment of Michael Heffernan as Chairman of the Board of Directors. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer of the Company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics initiated with a Buy at Stifel
- Avalo Therapeutics initiated with a Buy at Jefferies
- Promising Outlook for Avalo Therapeutics’ AVTX-009 in HS Treatment
- Promising Investment Opportunity in Avalo Therapeutics: Strong Financial Position and Breakthrough HS Treatment
- Avalo Therapeutics reports FY24 EPS ($20.91) vs ($113.58) last year